Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial [Brief Reports]
Conclusions—
We observed a potential late treatment effect for prasugrel versus clopidogrel for a reduced risk of ischemic stroke in medically managed patients with ACS aged <75 years. These hypothesis-generating findings suggest that longer duration and more potent platelet inhibition with prasugrel may be associated with lower risk of ischemic stroke after 12 months.
Clinical Trial Registration—
URL: http://www.clinicaltrials.gov. Unique identifier: NCT00699998.
Source: Stroke - Category: Neurology Authors: Chin, C. T., Neely, B., Magnus Ohman, E., Armstrong, P. W., Corbalan, R., White, H. D., Prabhakaran, D., Winters, K. J., Fox, K. A. A., Roe, M. T., for the TRILOGY ACS Investigators Tags: Cerebrovascular Disease/Stroke, Acute Coronary Syndromes Brief Reports Source Type: research
More News: Aspirin | Clinical Trials | Clopidogrel | Hemorrhagic Stroke | Ischemic Stroke | Neurology | Plavix | Stroke